References

Claudins in Cancer: a current and future therapeutic target

10.3390/ijms25094634 · 2024 · External reference

Heterogeneity of claudin 18.2 expression in metastatic gastric cancer

2024 · External reference

Claudin 18.2 as a new biomarker in gastric cancer—What should we know?

10.3390/cancers16030679 · 2024 · External reference

Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

2026 · External reference

Claudin 18.2 as a novel therapeutic target

10.1038/s41571-024-00874-2 · 2024 · External reference

Liquid biopsy: an innovative tool in oncology. Where do we stand?

10.1016/j.seminoncol.2025.152343 · 2025 · External reference

CLDN18.2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer

10.1053/j.gastro.2023.06.037 · 2023 · External reference

Tumor tough, therapy smarter: rethinking CAR-T for pancreatic cancer

10.1016/j.seminoncol.2025.152411 · 2025 · External reference

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

10.1016/j.esmoop.2022.100762 · 2023 · External reference

Pancreatic Cancer: a review

10.1001/jama.2021.13027 · 2021 · External reference

Harnessing epigenetic inhibitors: a promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment

10.1016/j.addr.2025.115638 · 2025 · External reference

Diagnostic performance of a tumor marker gene test to personalize serum CA19–9 reference ranges

10.1158/1078-0432.ccr-23-0655 · 2023 · External reference

Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an E-selectin ligand in non-small cell lung cancer

10.3892/ijo.2019.4886 · 2019 · External reference

Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma

10.1038/s41598-025-00517-1 · 2025 · External reference

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis

10.1016/j.ebiom.2021.103541 · 2021 · External reference

Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis

10.1080/1354750x.2020.1725786 · 2020 · External reference

Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management

10.18632/oncotarget.28566 · 2024 · External reference

CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC)

10.1038/s41416-021-01431-9 · 2021 · External reference

Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2

10.1016/j.canlet.2024.217362 · 2025 · External reference

Recent discoveries of diagnostic, prognostic and predictive biomarkers for pancreatic cancer

10.3390/cancers12113234 · 2020 · External reference

Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis

10.3748/wjg.v21.i14.4323 · 2015 · External reference

Advances in the application of extracellular vesicles in precise diagnosis of pancreatic cancer

10.1186/s40001-025-02739-5 · 2025 · External reference

Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

10.1038/s41598-025-31838-w · 2025 · External reference

Triple-negative breast cancer EVs modulate growth and migration of normal epithelial lung cells

10.3390/ijms25115864 · 2024 · External reference

Differential extracellular vesicle concentration and their biomarker expression of integrin αv/β5, EpCAM, and glypican-1 in pancreatic cancer models

10.1038/s41598-024-65209-8 · 2024 · External reference

Screening of exosome-derived proteins and their potential as biomarkers in diagnostic and prognostic for pancreatic cancer

10.3390/ijms241612604 · 2023 · External reference

Potential clinical applications of extracellular vesicles in pancreatic cancer: exploring untapped opportunities from biomarkers to novel therapeutic approaches

10.20517/evcna.2023.68 · 2024 · External reference

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

10.1038/nature14581 · 2015 · External reference

Evidence for the need to evaluate more than one source of extracellular vesicles, rather than single or pooled samples only, when comparing extracellular vesicles separation methods

10.3390/cancers13164021 · 2021 · External reference

Raman spectroscopy characterization extracellular vesicles from bovine placenta and peripheral blood mononuclear cells

2020 · External reference

Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens

10.1016/j.jlb.2023.100133 · 2024 · External reference

EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research

10.1038/nmeth.4185 · 2017 · External reference

Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with Claudin-18 overexpression

10.3390/jcm12165394 · 2023 · External reference

Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies

10.1080/21688370.2024.2348852 · 2025 · External reference

10.1073/pnas.0809966105

10.1073/pnas.0809966105 · External reference

Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues

10.1016/j.jpba.2020.113546 · 2020 · External reference

Regulation of epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: role of key molecules in tumor differentiation and therapy

10.1016/j.ejca.2025.115561 · 2025 · External reference

Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits

10.1038/s42003-021-02934-0 · 2022 · External reference

Claudins: from gatekeepers of epithelial integrity to potential targets in hepato-pancreato-biliary cancers

10.3389/fonc.2024.1454882 · 2024 · External reference

Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer

10.1186/1471-2407-9-244 · 2009 · External reference

Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma

10.1038/s41598-021-81023-y · 2021 · External reference

Distinct origin of claudin7 in early tumor endosomes affects exosome assembly

10.7150/ijbs.35347 · 2019 · External reference

Claudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells

10.1002/ijc.32312 · 2019 · External reference

Fucosylated TGF-β receptors transduces a signal for epithelial–mesenchymal transition in colorectal cancer cells

10.1038/bjc.2013.699 · 2014 · External reference

Claudin and pancreatic cancer

2023 · External reference

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer

2023 · External reference

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: assessment of a potential clinical biomarker for zolbetuximab therapy

10.1016/j.tranon.2025.102362 · 2025 · External reference

Structure, function, and implications of fucosyltransferases in health and disease

10.1038/s41467-025-66871-w · 2025 · External reference

High fidelity of claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy

10.1016/j.humpath.2025.106014 · 2026 · External reference

Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma

10.1007/bf02890431 · 1992 · External reference

The forces driving cancer extracellular vesicle secretion

10.1016/j.neo.2020.11.011 · 2021 · External reference